Anavex Life Sciences's (NASDAQ:AVXL) short percent of float has risen 17.06% since its last report. The company recently reported that it has 11.91 million shares sold short, which is 15.71% of all regular shares that are available for trading.
Cantor Fitzgerald analyst Charles Duncan downgrades Anavex Life Sciences (NASDAQ:AVXL) from Overweight to Neutral and lowers the price target from $16 to $11.